Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125502 | 0.97 | RAB9A (0.66) | RAB9ANPC1SIRT2SIRT1L3MBTL1 | |
| SCHEMBL4131531 | 0.89 | L3MBTL1 (0.56) | RAB9ANPC1L3MBTL1HPGDPTGER4 | |
| SCHEMBL4135018 | 0.88 | SIRT2 (0.51) | RAB9ANPC1SIRT2SIRT1L3MBTL1 | |
| SCHEMBL4129907 | 0.86 | SIRT2 (0.49) | RAB9ANPC1SIRT2SIRT1L3MBTL1 | |
| SCHEMBL13905293 | 0.85 | HPGD (0.52) | RAB9ANPC1L3MBTL1HPGD | |
| SCHEMBL4116973 | 0.85 | L3MBTL1 (0.56) | RAB9ANPC1L3MBTL1HPGDPTGER4 | |
| SCHEMBL13905294 | 0.85 | RAB9A (0.48) | RAB9ANPC1L3MBTL1MEN1KMT2A | |
| SCHEMBL4124665 | 0.85 | BMPR2 (0.44) | RAB9ANPC1L3MBTL1HPGD | |
| SCHEMBL4130107 | 0.84 | L3MBTL1 (0.44) | RAB9ANPC1L3MBTL1HPGDPTGER4 | |
| SCHEMBL13904927 | 0.84 | OPRM1 (0.48) | RAB9ANPC1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | RAB9A 1453/4885NPC1 2924/4885SIRT2 2626/4885 |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | RAB9A 893/4885NPC1 149/4885SIRT2 1825/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | RAB9A 893/4885NPC1 149/4885SIRT2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.